Cabergoline has helped the vast majority of women with high prolactin levels conceive, with pregnancy rates reaching into the 80s and 90s percent range in published clinical studies. The drug works by lowering prolactin, the hormone that, when chronically elevated, shuts down ovulation and menstrual cycles. For women whose infertility traces back to a prolactinoma or other cause of hyperprolactinemia, the clinical literature paints a consistently encouraging picture, though the path from diagnosis to a healthy delivery involves decisions about dosing, timing, and monitoring that deserve a closer look.
How Cabergoline Restores the Ability to Conceive
Prolactin is the hormone responsible for milk production, but when levels stay elevated outside of pregnancy and breastfeeding, it suppresses the hormonal signals that trigger ovulation. The result is irregular or absent periods, and without ovulation, pregnancy is off the table. Cabergoline acts on dopamine receptors in the pituitary gland, which brings prolactin levels down. In women who have a prolactinoma, the drug also shrinks the tumor itself. A meta-analysis comparing cabergoline to bromocriptine (the older standard treatment) found cabergoline was significantly better at normalizing prolactin and restoring ovulatory menstrual cycles.1PubMed. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis
The practical upshot is that once prolactin drops into the normal range and regular cycles return, the biological barrier to conception is removed. For many women, this happens within a few months of starting cabergoline. One study found menstruation was restored in an average of about 3.6 months on cabergoline, compared to nearly 6 months on bromocriptine.2BioMedica. Cabergoline: an effective treatment for conception in prolactinoma That speed matters when you are trying to get pregnant and every cycle feels like it counts.
What the Pregnancy Rates Actually Look Like
The numbers from clinical studies are striking. In a study of 85 infertile women with prolactinomas, including both small (micro) and large (macro) tumors, cabergoline normalized prolactin and restored ovulatory cycles in every single patient. Eighty of those 85 women conceived, a rate of about 94%. That included women who had previously failed or could not tolerate bromocriptine.3The Journal of Clinical Endocrinology & Metabolism. Individualized High-Dose Cabergoline Therapy for Hyperprolactinemic Infertility in Women with Micro- and Macroprolactinomas A larger prospective study of over 300 women with prolactinomas reported pregnancies in 95% of subjects, resulting in 345 healthy births.4Journal of the Endocrine Society. SAT-091 Individualized-dose Cabergoline Therapy for 310 Prolactinomas: Prospective Study on Pregnancy, Debulking, Remission and Optimal Dosing
These are not cherry-picked results from ideal patients. The studies included women with macroprolactinomas, women who had been resistant to bromocriptine, and women who could not tolerate the side effects of older treatments. The consistency across different research groups and populations is part of what makes the evidence persuasive. That said, these studies followed women specifically under specialist endocrinology care, where dosing was carefully adjusted and pregnancy was timed after adequate tumor shrinkage. The pregnancy rates in routine clinical practice may be somewhat lower simply because of less intensive monitoring.
Cabergoline Versus Bromocriptine
Bromocriptine was the go-to treatment for hyperprolactinemia for decades, and it is still widely used. But head-to-head comparisons consistently favor cabergoline on every outcome that matters to someone trying to conceive. A landmark trial published in the New England Journal of Medicine found that cabergoline normalized prolactin in about 83% of women, versus 59% on bromocriptine. Ovulatory cycles or pregnancy occurred in 72% of cabergoline-treated women compared to 52% on bromocriptine.5PubMed. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
A study focused on women undergoing intrauterine insemination found that 82% of those on cabergoline became pregnant, compared to about 56% of those on bromocriptine.6PubMed. A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination Live birth rates also tend to be higher: one study reported 84% with cabergoline versus about 73% with bromocriptine.7BioMedica. Cabergoline: an effective treatment for conception in prolactinoma
Beyond efficacy, tolerability is a real factor. Bromocriptine is infamous for causing nausea, dizziness, and fatigue, and about 12% of women in the NEJM trial stopped taking it because of side effects. Only 3% discontinued cabergoline for the same reason.8PubMed. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea Cabergoline also has the practical advantage of being taken just once or twice a week, rather than daily. When you are already dealing with the stress of infertility, fewer pills and fewer side effects matter.
Is Cabergoline Safe for the Baby?
This is the question that causes the most anxiety, and understandably so. The standard clinical approach has been to stop cabergoline once pregnancy is confirmed, which means the fetus is typically exposed only during the first few weeks before a woman even knows she is pregnant. The safety data on that early exposure is now reassuringly large.
A review covering more than 900 pregnancies with early cabergoline exposure found no increase in miscarriage, premature delivery, or neonatal malformations, with follow-up of children extending up to 12 years showing normal physical and developmental outcomes.9PubMed. Prolactinoma and pregnancy: From the wish of conception to lactation A systematic review that pooled data across 12 studies and over 1,600 pregnancies exposed to cabergoline found that major malformations occurred in about 2.1% of cabergoline-exposed pregnancies, compared to 3.3% in the bromocriptine group. None of the studies found a statistically significant difference from what you would expect in the general population. Spontaneous abortion rates averaged roughly 8.6% in cabergoline-exposed pregnancies, again within the range of the general population.10PubMed Central. Cabergoline Use and Pregnancy Outcomes: A Systematic Review
Another study specifically tracking 100 pregnancies conceived on cabergoline reported a malformation rate of about 3.4% among the 88 infants delivered, compared to 6.3% in a control group. Postnatal development was normal.11PubMed. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women A more recent meta-analysis confirmed no significant differences in congenital malformations, preterm birth, or low birth weight between cabergoline-exposed pregnancies and comparators.12PubMed. Safety of Cabergoline for Prolactinoma in Pregnancy: A Systematic Review and Meta-Analysis
A study of 103 pregnancies found a miscarriage rate of about 7.2%, and the three neonatal abnormalities observed included one case of Down syndrome (a chromosomal condition unrelated to drug exposure) and two minor issues. The authors concluded there was no higher frequency of complications than in the normal population.13PubMed. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature
The evidence is not based on randomized controlled trials assigning pregnant women to cabergoline versus placebo, because that kind of trial would be unethical. Instead, it comes from large observational datasets and retrospective analyses. But the consistency of the findings across many different studies and populations is what gives clinicians confidence. Cabergoline data on pregnancy does not carry the same depth of long-term evidence as bromocriptine (which has been used since the 1970s), but the gap is narrowing.
When to Stop and What Happens to the Tumor
The typical protocol is to stop cabergoline as soon as pregnancy is confirmed. There are no formal expert guidelines mandating this, and the practice is driven more by caution than by evidence of harm.14PubMed Central. Cabergoline Use and Pregnancy Outcomes: A Systematic Review For women with microadenomas (small tumors under 1 cm), this is usually straightforward. The risk of a microadenoma growing enough during pregnancy to cause problems is around 3%.15PubMed Central. Managing Prolactinomas during Pregnancy
The picture is different for macroadenomas. When a larger tumor has not been previously treated with surgery, the risk of clinically significant growth during pregnancy jumps to about 32%. If the macroadenoma was treated with surgery before pregnancy, the risk drops to under 5%.16PubMed Central. Managing Prolactinomas during Pregnancy This is why many specialists will not green-light pregnancy until a macroadenoma has been adequately debulked with medication. In one protocol, women with macroadenomas withheld pregnancy attempts until the tumor shrank below 1 cm in height.17The Journal of Clinical Endocrinology & Metabolism. Individualized High-Dose Cabergoline Therapy for Hyperprolactinemic Infertility in Women with Micro- and Macroprolactinomas Another study used an even more precise criterion, requiring that the distance between the tumor and the optic nerve crossing point be adequate before permitting conception.18Journal of the Endocrine Society. SAT-091 Individualized-dose Cabergoline Therapy for 310 Prolactinomas: Prospective Study on Pregnancy, Debulking, Remission and Optimal Dosing
For the small number of women with macroadenomas who develop symptoms of tumor growth during pregnancy, such as severe headaches or visual changes, the treatment can be restarted. In about ten reported cases where cabergoline was continued throughout the entire pregnancy, no evidence of harm to the baby was found.19PubMed. Prolactinomas, cabergoline, and pregnancy One case report documented a woman who took cabergoline through all three trimesters with monitoring at each stage, and the outcome was uneventful.20PubMed Central. Management of prolactinoma with cabergoline treatment in a pregnant woman during her entire pregnancy These scenarios are uncommon, but it is useful to know that the option exists if needed.
Women Who Need Higher Doses
Not everyone responds to the low standard dose of cabergoline. Women who previously failed bromocriptine, or who have larger tumors, often require substantially more. In the large prospective study of over 300 patients, the dose needed to achieve response varied significantly depending on the clinical situation. Women who were intolerant of bromocriptine responded at relatively low cabergoline doses (around 0.66 mg per week on average), while those who were resistant to bromocriptine needed much higher doses, around 3.3 mg per week. Tumor size mattered too: microadenomas responded at lower doses than macroadenomas.21Journal of the Endocrine Society. SAT-091 Individualized-dose Cabergoline Therapy for 310 Prolactinomas: Prospective Study on Pregnancy, Debulking, Remission and Optimal Dosing
The key point is that even women who are considered resistant to treatment can often be brought to normal prolactin levels with individualized, higher dosing. The pregnancy rates in these studies included such patients, which is partly why the results are so encouraging. If a standard dose is not working, that does not necessarily mean cabergoline has failed; it may mean the dose has not been pushed high enough under specialist supervision.
Cabergoline’s Role Beyond Prolactinomas
Some of the most interesting findings about cabergoline and fertility have come from women who do not have elevated prolactin at all. In women with polycystic ovary syndrome (PCOS) and normal prolactin levels, adding a small dose of cabergoline to the standard ovulation-induction drug clomiphene citrate improved results significantly. One randomized trial found that the combination achieved a cumulative ovulation rate of about 77%, compared to about 58% with clomiphene alone, and a clinical pregnancy rate of about 32% versus 13%.22Middle East Fertility Society Journal. Clomiphene citrate plus cabergoline versus clomiphene citrate for induction of ovulation in infertile euprolactinemic patients with polycystic ovary syndrome: A randomized clinical trial Another trial confirmed these findings, showing improved ovulation and pregnancy rates with minimal additional side effects.23PubMed. Improving pregnancy rate in infertile patients with polycystic ovarian syndrome receiving clomiphene citrate and cabergoline in euprolactinomic women in single cycle treatment
Cabergoline also has a role in IVF cycles, though not for inducing pregnancy directly. It is used to prevent ovarian hyperstimulation syndrome (OHSS), a potentially dangerous complication of ovarian stimulation. One study found that OHSS occurred in 12% of women given cabergoline after egg retrieval, compared to 36% in the control group, with no negative effects on pregnancy outcomes.24PubMed Central. The effectiveness of cabergoline for the prevention of ovarian hyperstimulation syndrome The mechanism here is different from its prolactin-lowering role: cabergoline reduces vascular permeability through its action on certain dopamine receptors in the ovaries.
What Happens After Delivery
One question that comes up less often but matters just as much: do you have to go back on cabergoline forever after having your baby? For a meaningful fraction of women, the answer is no. Pregnancy and breastfeeding appear to trigger lasting remission in some cases. In a cohort of women who stopped cabergoline during pregnancy, about 42% had normal prolactin levels after pregnancy and lactation, qualifying as being in remission.25PubMed Central. Prolactinoma Outcome After Pregnancy and Lactation: A Cohort Study A separate study of 73 women found a remission rate of about 41% over a median follow-up of nearly two years after delivery.26PubMed. Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients
A few factors seem to predict who achieves remission. Longer pre-pregnancy treatment with cabergoline helped: women who had been treated for a median of five years before pregnancy were more likely to stay in remission than those treated for only two years. Smaller tumors before pregnancy also predicted better outcomes.27PubMed Central. Prolactinoma Outcome After Pregnancy and Lactation: A Cohort Study Interestingly, the number of pregnancies and whether or how long a woman breastfed did not seem to influence remission rates.28PubMed. Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients Not every study is as optimistic: a third found remission after about 26% of pregnancies, with 25% of women still in remission at last follow-up.29PubMed. An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists Still, the possibility that pregnancy could be the beginning of the end of needing medication is something many women find encouraging.
Heart Valve Concerns and Why They Probably Do Not Apply Here
If you have researched cabergoline online, you may have come across alarming mentions of heart valve damage. This concern is real, but it comes from a different clinical context. Patients with Parkinson’s disease take cabergoline at vastly higher doses (often 3 mg or more per day) for years. At those cumulative exposures, there is a documented risk of fibrotic changes to heart valves. Prolactinoma patients typically take a fraction of that dose, often 0.5 to 2 mg per week.
A study specifically looking at cardiac valve function in prolactinoma patients on long-term cabergoline found only mild valve changes in a handful of patients, with no cases of significant (moderate to severe) regurgitation, and no structural abnormalities like valve thickening or calcification.30PubMed Central. Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma Most endocrinology guidelines now recommend periodic echocardiograms for patients on higher doses or very long-term therapy, but for the typical woman taking cabergoline at standard prolactinoma doses for a few years before and between pregnancies, the valve risk appears to be negligible. It is still worth discussing with your endocrinologist, especially if you anticipate needing high-dose or indefinite treatment.
When Cabergoline Alone Is Not Enough
It is worth acknowledging that cabergoline does not guarantee pregnancy for everyone. About 5 to 10% of women with prolactinomas may not achieve normal prolactin even on high doses. Some women conceive on cabergoline but have coexisting fertility issues, such as tubal problems or a partner’s sperm quality, that require additional treatment. The studies reporting 90%+ pregnancy rates selected specifically for women whose only identified fertility barrier was high prolactin, so those numbers should be understood in that context.
Women whose hyperprolactinemia is caused by something other than a prolactinoma, such as certain medications or hypothyroidism, will need those underlying issues addressed first. Cabergoline can lower prolactin in those situations too, but the fertility outcome depends on fixing the root cause. Age also plays a role that cabergoline cannot override: ovarian reserve declines regardless of prolactin status, and a woman in her late 30s or 40s faces age-related fertility challenges on top of anything caused by elevated prolactin.
For couples who have been told that high prolactin is the barrier, though, the clinical evidence on cabergoline is genuinely encouraging. The pregnancy rates are high, the safety record for the baby is strong across hundreds of documented pregnancies, and a meaningful number of women find they no longer need the medication after pregnancy. Few fertility-adjacent treatments have this kind of consistent track record across multiple independent research groups.